Fat excretion after intake of a polyglucosamine: an observational study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00004851

Enrollment

Registered

2014-07-21

Start date

2014-01-30

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obesity E66

Interventions

Group 1: formoline L112: 2 tablets (500mg each) before lunch and 2 tablets before dinner over a period of 6 days

collection of fecal samples and analysis of fat amount/fatty acid pattern

Eligibility

Sex/Gender

All

Age

25 Years to 70 Years

Inclusion criteria

Inclusion criteria: BMI 25 – 35 kg/m2, Stable bodyweight (± 2 kg in the last 3 months), wirtten informed consent

Exclusion criteria

Exclusion criteria: severe general disease, present obstipation, congestion, known to be allergic to crustacean or to another ingredient, gut surgery mentioned in the anamnesis, psychiatric disorders

Design outcomes

Primary

Measure	Time frame
Fat excretion in the faeces is measured at the beginning and at the end of the 6-days intake. Fat is extracted by HCL and weighed afterwards.	—

Countries

Germany

Contacts

Public ContactYu-Mi Lee

Else Kröner-Fresenius-Zentrum für Ernährungsmedizin der TU München Lehrstuhl für Ernährungsmedizin

ylee@wzw.tum.de08161-712007

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026